A Study to Investigate the Pharmacokinetics of Ethinyl Estradiol and Levonorgestrel When Given Alone and in Combination With Baxdrostat in Healthy Females of Non-childbearing Potential

Inclusion Criteria: * Females must have a negative pregnancy test at the Screening Visit and Study Day -1 (admission to Clinical Unit) and must not be lactating and must be of non-childbearing potential, confirmed at Screening by fulfilling one of the following criteria: 1. Postmenopausal defined as amenorrhea for at least 12 months following cessation of all exogenous hormonal treatments and FSH levels in the postmenopausal range (Follicular Stimulating Hormone (FSH) \> 40 mIU/mL). 2. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation or tubal occlusion. * Have a Body Mass Index (BMI) between 18 and 30 kg/m2 Exclusion Criteria: * History of any clinically important disease or disorder which, in the opinion of the Investigator * History or presence of gastrointestinal, hepatic, or renal disease or any other condition known to interfere with absorption, distribution, metabolism, or excretion of drugs. * Sex hormone therapy within one month before study. * History of drug-related hepatic toxicity. * History or family history of potential risk of arterial and venous thromboembolic events (eg, factor V Leiden mutation). * History of cardiovascular risk (eg, history of myocardial infarction). * Any laboratory values with the following deviations at the Screening Visit and Study Day -1 (admission to Clinical Unit). * Any positive result on screening for serum HBsAg, HBcAb, HCV or HIV. * History of any treatment with QT prolongation drugs. * Current smokers or know history of alcohol or drug abuse. * History or ongoing severe allergy/hypersensitivity. * An increased risk for developing SAEs or a contraindication associated with administration of EE, or LNG such as history of thrombosis or thromboembolism, presence of estrogen dependent tumors, hypertension, migraines, and liver disease. * Participants treated with strong CYP3A4 inhibitors or inducers within 3 months or longer (5 half-lives) prior to first administration of IMP in this study. * Plasma donation within one month of the Screening Visit or any blood donation/blood loss \> 500 mL during the 3 months prior to the Screening Visit. * Has received another new chemical entity (defined as a compound which has not been approved for marketing) within 30 days or 5 half-lives (whichever is longest) of the first administration of IMP in this study. * Participants who are vegans or have medical dietary restrictions and vulnerable participants.